Breaking News Instant updates and real-time market news.

ONCS

OncoSec

$2.50

-0.11 (-4.21%)

08:32
06/27/19
06/27
08:32
06/27/19
08:32

OncoSec enters collaboration with Dana-Farber Cancer Institute

OncoSec Medical announced that it has entered into a collaboration with Dana-Farber Cancer Institute, and The Marasco Laboratory, a cutting-edge CAR T-cell research laboratory led by Wayne Marasco, M.D., Ph.D., a renowned cancer immunology researcher, to develop CAR T-cell therapies for triple-negative breast cancer and other solid tumor cancers. Under the terms of the agreement, OncoSec has acquired an exclusive option to licensing rights to the CAR T-cell product candidates and associated IP resulting from the research being conducted at The Marasco Laboratory using engineered single-chain variable fragment antibodies in a dual-targeted bi-specific CAR T-cell approach. Previous research conducted by The Marasco Laboratory suggests their proprietary CAR T-cell technology has the potential to be effective against numerous solid tumor indications, while minimizing the toxicity that current CAR T-cell technologies exhibit when applied beyond liquid tumor indications. The company plans to begin clinical trials with the TNBC CAR T-cell therapy in 2020, both as a monotherapy and in combination with OncoSec's TAVO.

ONCS OncoSec
$2.50

-0.11 (-4.21%)

05/22/19
05/22/19
NO CHANGE

OncoSec interim Phase II data 'compelling,' says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff maintained an Overweight rating on OncoSec shares after the company's interim Phase II KEYNOTE-890 data for TAVO IL-12 plus Keytruda in ten evaluable TNBC, or triple-negative breast cancer, patients showed two partial responses and four patients with stable disease at three-months. The analyst noted that full results are expected in the second half of the year. Tenthoff reset his price target on share to $8 from $30 split adjusted "due to dilution from recent financing." The lower price target is "based on $104M enterprise value, down from $225M."
02/01/19
PIPR
02/01/19
NO CHANGE
Target $3
PIPR
Overweight
Piper says OncoSec's TAVO resensitizing anti-PD-1 progressers 'impressive'
After OncoSec (ONCS) reported updated data for the registrational KEYNOTE-695 study evaluating TAVO plus Merck's (MRK) Keytruda, Piper Jaffray analyst Edward Tenthoff noted that TAVO's ORR improved and called the fact that TAVO resensitized anti-PD-1 progressers "impressive." He reiterates an Overweight and $3 price target on OncoSec shares.
12/12/18
PIPR
12/12/18
NO CHANGE
Target $3
PIPR
Overweight
Piper reiterates Overweight, $3 target on OncoSec after data
Piper Jaffray analyst Edward Tenthoff believes OncoSec Medical's updated six-month response data from the Phase IIb Keynote-695 data of tavo plus Keytruda in PD-1 refractory melanoma demonstrate tavo's ability to deepen tumor response over time. The analyst reiterates an Overweight rating on OncoSec with a $3 price target.
11/07/18
HCWC
11/07/18
DOWNGRADE
Target $1
HCWC
Neutral
OncoSec downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju downgraded OncoSec to Neutral from Buy after the company reported preliminary top-line data from the PISCES/KEYNOTE-695 trial of TAVO with Keytruda in metastatic melanoma patients who have failed anti-PD-1 therapy, stating that his first impression is that the early efficacy results are "underwhelming." He noted that other second generation I/O agents have demonstrated higher response rates and while TAVO may eventually obtain regulatory approval, its efficacy may not be differentiated enough for wide market adoption. Selvaraju lowered his price target on OncoSec shares to $1 from $4.

TODAY'S FREE FLY STORIES

VAR

Varian Medical

$134.22

-0.72 (-0.53%)

, VRAY

ViewRay

$9.31

0.16 (1.75%)

12:49
07/17/19
07/17
12:49
07/17/19
12:49
Recommendations
Varian Medical, ViewRay analyst commentary  »

Competitor recall…

VAR

Varian Medical

$134.22

-0.72 (-0.53%)

VRAY

ViewRay

$9.31

0.16 (1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 09

    Sep

TTWO

Take-Two

$118.37

0.88 (0.75%)

12:43
07/17/19
07/17
12:43
07/17/19
12:43
Earnings
Stephens, Cowen up Take-Two price targets ahead of Q1 results »

Take-Two (TTWO) shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 05

    Aug

  • 05

    Sep

  • 13

    Nov

SSRM

SSR Mining

$14.72

0.665 (4.73%)

12:25
07/17/19
07/17
12:25
07/17/19
12:25
Options
SSR Mining call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:25
07/17/19
07/17
12:25
07/17/19
12:25
General news
Treasury Action: the downdraft in European rates has helped pulling Treasury yields lower »

Treasury Action: the…

CAPR

Capricor Therapeutics

$6.39

0.48 (8.12%)

12:25
07/17/19
07/17
12:25
07/17/19
12:25
Conference/Events
Capricor Therapeutics to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

IBM

IBM

$142.94

-0.6 (-0.42%)

12:24
07/17/19
07/17
12:24
07/17/19
12:24
Earnings
Fly Intel: What to watch in IBM's earnings report »

IBM (IBM) is scheduled to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

AMZN

Amazon.com

$1,999.39

-10.61 (-0.53%)

, QCOM

Qualcomm

$76.74

1.08 (1.43%)

12:23
07/17/19
07/17
12:23
07/17/19
12:23
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks have dropped in…

AMZN

Amazon.com

$1,999.39

-10.61 (-0.53%)

QCOM

Qualcomm

$76.74

1.08 (1.43%)

MSFT

Microsoft

$137.11

0.03 (0.02%)

T

AT&T

$33.47

-0.1 (-0.30%)

BAC

Bank of America

$29.47

0.475 (1.64%)

CSX

CSX

$71.11

-8.46 (-10.63%)

ABT

Abbott

$86.33

3.22 (3.87%)

SGEN

Seattle Genetics

$73.43

10.31 (16.33%)

INO

Inovio

$2.65

-0.35 (-11.67%)

NUS

Nu Skin

$37.95

-7.55 (-16.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 18

    Jul

  • 24

    Jul

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 06

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 08

    Aug

  • 26

    Aug

  • 06

    Sep

  • 09

    Sep

  • 13

    Nov

KSU

Kansas City Southern

$118.05

-4.78 (-3.89%)

12:18
07/17/19
07/17
12:18
07/17/19
12:18
Downgrade
Kansas City Southern rating change  »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 13

    Nov

NSC

Norfolk Southern

$194.90

-11.63 (-5.63%)

12:18
07/17/19
07/17
12:18
07/17/19
12:18
Downgrade
Norfolk Southern rating change  »

Norfolk Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 26

    Aug

CSX

CSX

$71.21

-8.36 (-10.51%)

12:18
07/17/19
07/17
12:18
07/17/19
12:18
Downgrade
CSX rating change  »

CSX downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 13

    Nov

UNP

Union Pacific

$166.50

-8.6 (-4.91%)

12:17
07/17/19
07/17
12:17
07/17/19
12:17
Downgrade
Union Pacific rating change at C.K. Cooper »

Union Pacific downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 26

    Aug

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
07/17/19
07/17
12:17
07/17/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
07/17/19
07/17
12:16
07/17/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTAP

NetApp

$59.31

0.36 (0.61%)

12:15
07/17/19
07/17
12:15
07/17/19
12:15
Options
NetApp put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
07/17/19
07/17
12:15
07/17/19
12:15
General news
Breaking General news story  »

Kansas City Federal…

CBB

Cincinnati Bell

$4.28

-0.44 (-9.32%)

12:00
07/17/19
07/17
12:00
07/17/19
12:00
Hot Stocks
Cincinnati Bell falls -9.5% »

Cincinnati Bell is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$21.02

-2.08 (-9.00%)

12:00
07/17/19
07/17
12:00
07/17/19
12:00
Hot Stocks
Direxion Daily Junior Gold Miners Index Bear 3x Shares falls -9.0% »

Direxion Daily Junior…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUS

Nu Skin

$38.13

-7.37 (-16.20%)

12:00
07/17/19
07/17
12:00
07/17/19
12:00
Hot Stocks
Nu Skin falls -16.0% »

Nu Skin is down -16.0%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

AG

First Majestic

$9.10

0.53 (6.18%)

12:00
07/17/19
07/17
12:00
07/17/19
12:00
Hot Stocks
First Majestic rises 6.2% »

First Majestic is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$70.17

5.71 (8.86%)

12:00
07/17/19
07/17
12:00
07/17/19
12:00
Hot Stocks
Direxion Daily Jr Gld Mnrs Bull 3X Shrs rises 8.7% »

Direxion Daily Jr Gld…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSM

Fortuna Silver Mines

$3.55

0.37 (11.65%)

12:00
07/17/19
07/17
12:00
07/17/19
12:00
Hot Stocks
Fortuna Silver Mines rises 11.6% »

Fortuna Silver Mines is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
07/17/19
07/17
11:55
07/17/19
11:55
General news
Oil Action: WTI crude »

Oil Action: WTI crude…

11:55
07/17/19
07/17
11:55
07/17/19
11:55
Conference/Events
Federal Reserve Bank of Kansas City to speak on economic outlook »

Kansas City Federal…

AVXL

Anavex

$3.03

(0.00%)

11:52
07/17/19
07/17
11:52
07/17/19
11:52
Hot Stocks
Anavex presents new clinical data identifying gut microbiota biomarkers »

Anavex Life Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$11.90

-0.01 (-0.08%)

11:50
07/17/19
07/17
11:50
07/17/19
11:50
Options
Call block in Caesar's noted as account swap from July 8th opener »

Call block in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.